Delivery Order SPE2DR25D2009-SPE2DR26FJ3T5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,867.55 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units). This firm fixed-price delivery order, executed on December 4, 2025, with completion targeted for December 5, 2025, represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $3,043.89 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Rexulti 3 mg tablets (30-count packages) under a firm fixed-price contract with a ceiling value of $6,528.83. This is a non-set-aside competitive award with an ultimate completion date of December 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $3,665.11 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on November 4, 2025, with completion scheduled for November 5, 2025. This is a firm fixed price, non-set-aside competitive award issued under an indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performs this work at its corporate office location. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packages) on December 10, 2025, with an ultimate completion date of December 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $26,659.20 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $2,927.91 delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreements. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.98 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. The order, awarded on October 24, 2025, with an ultimate completion date of October 27, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This IDC, valued at $999.999 billion and extending through...
- SPE2DR25D2009Indefinite Delivery Contract
- SPE2DR25D2009-SPE2DR26FJ3T5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,806.14 to AmerisourceBergen Drug Corp for the supply of Rexulti 3 mg tablets (30-count units) on December 3, 2025, with completion scheduled for December 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical prime vendor supporting federal medical supply chains. As a major pharmaceutical distributor, the company serves the Defense Health Agency and other government healthcare systems through its comprehensive IDC vehicle, which enables supply of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs globally. The award of this specific order for Rexulti, an antipsychotic medication, reflects the company's ongoing role in delivering pharmaceutical products essential to military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 12/2/25 |